CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Eprosartan mesylate/ hydrochlorothiazide

Last Updated: July 8, 2004
Result type: Reports
Project Number: S0016
Product Line: Reimbursement Review

Generic Name: Eprosartan mesylate/ hydrochlorothiazide

Brand Name: Teveten Plus

Manufacturer: Solvay Pharma Inc.

Indications: Hypertension, Essential

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: December 15, 2004

Recommendation Type: List in a similar manner to other drugs in class